A Phase III, Multicenter, randomized, visual,assessor-masked, active-comparator study of the efficacy,safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with neovascularage-related macular degeneration.

Project: Research project

Description

A Phase III, Multicenter, randomized, visual,assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration.
StatusActive
Effective start/end date10/31/1812/31/19

Funding

  • Genentech Inc.

Fingerprint

Macular Degeneration
Pharmacokinetics
Safety
Ranibizumab